Shizane's Accounts

[Shizane]

NEWS: NAVB. OMED, REGN, GHDX, SNTS, AVNR, VRTX, CYTK

NAVB

Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program

OMED

OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

REGN

Regeneron Pharms initiated with a Outperform at Oppenheimer; tgt $300

7:14 AM ET 8/22/13 | Briefing.com

. Oppenheimer initiates REGN with a Outperform and price target of $300. They expect near-term growth to continue as Eylea gains broader adoption in wet AMD and expands into a new indication, DME, in 2014. They are focused on REGN727, a PCSK9 inhibitor that could fulfill a huge unmet need in hypercholesterolemia, representing another blockbuster opportunity. Given the strength of its pipeline and an unmatched platform for antibody discovery, they view REGN as a core Biotech holding with meaningful potential for upside.

GHDX

Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit

SNTS

Analyst: Leerink Swann Downgrade NASDAQ: SNTS Santarus Old: Outperform New: Market Perform

AVNR

Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings

VRTX

Analysts' Actions: MSFT PCP TSLA VRTX ZNGA

CYTK

Cytokinetics publishes results from tirasemtiv Phase II trials in ALS patients